Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sacituzumab”

177 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 177 results

Testing effectiveness (Phase 2)Looking for participantsNCT06401824
What this trial is testing

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Who this might be right for
NSCLC Stage IVBrain Metastases, Adult
Maastricht University Medical Center 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07438626
What this trial is testing

Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma

Who this might be right for
Phase IISacituzumabTirumotecan+1 more
M.D. Anderson Cancer Center 20
Large-scale testing (Phase 3)Active Not RecruitingNCT04595565
What this trial is testing

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Who this might be right for
HER2-negative Breast CancerTriple Negative Breast Cancer
GBG Forschungs GmbH 1,332
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07271992
What this trial is testing

TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer

Who this might be right for
TNBC, Triple Negative Breast Cancer
First Hospital of China Medical University 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07343479
What this trial is testing

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Gene MutationsBrain Metastasis
Zhejiang Cancer Hospital 45
Testing effectiveness (Phase 2)Looking for participantsNCT07339059
What this trial is testing

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Cancer ( SCLC )Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Bindu R Potugari 35
Testing effectiveness (Phase 2)Looking for participantsNCT06682728
What this trial is testing

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

Who this might be right for
Urothelial CarcinomaMuscle-invasive Bladder Cancer
University of California, Irvine 23
Testing effectiveness (Phase 2)Active Not RecruitingNCT05101096
What this trial is testing

Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Triple-Negative Breast CancerHR+/HER2- Metastatic Breast Cancer+1 more
Gilead Sciences 135
Testing effectiveness (Phase 2)Looking for participantsNCT06238921
What this trial is testing

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Who this might be right for
Breast CancerTriple Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 31
Testing effectiveness (Phase 2)Study completedNCT05226117
What this trial is testing

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

Who this might be right for
Urothelial Carcinoma
IRCCS San Raffaele 44
Testing effectiveness (Phase 2)Active Not RecruitingNCT04826341
What this trial is testing

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Who this might be right for
HRD CancerSCLCAdvanced Solid Tumors
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Ended earlyNCT06865677
What this trial is testing

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Who this might be right for
Recurrent Platinum Resistant Epithelial Ovarian CarcinomaRecurrent Epithelial Endometrial CarcinomaRecurrent Epithelial Cervical Carcinoma
National Cancer Institute (NCI) 2
Large-scale testing (Phase 3)Active Not RecruitingNCT06356311
What this trial is testing

Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Who this might be right for
Gastroesophageal Cancer
Merck Sharp & Dohme LLC 450
Large-scale testing (Phase 3)Not Yet RecruitingNCT07628504
What this trial is testing

Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations

Who this might be right for
Adjuvant Drug Therapy
Fudan University 420
Testing effectiveness (Phase 2)Looking for participantsNCT06878625
What this trial is testing

A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer

Who this might be right for
Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 138
Testing effectiveness (Phase 2)Active Not RecruitingNCT06612203
What this trial is testing

Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
MedSIR 76
Not applicableNot Yet RecruitingNCT06798506
What this trial is testing

Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer

Who this might be right for
TNBC - Triple-Negative Breast Cancer
Fudan University 300
Testing effectiveness (Phase 2)Ended earlyNCT04927884
What this trial is testing

Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Who this might be right for
Advanced Triple Negative Breast Cancer
ImmunityBio, Inc. 3
Large-scale testing (Phase 3)Looking for participantsNCT05633654
What this trial is testing

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Who this might be right for
Triple Negative Breast Cancer
Gilead Sciences 1,514
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07348861
What this trial is testing

A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer

Who this might be right for
Cervical Cancer
Zheng Min 25
Load More Results